🚀 VC round data is live in beta, check it out!
Camurus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Camurus and similar public comparables like Travere Therapeutics, ACADIA Pharmaceuticals, Ajanta Pharma, Voronoi and more.
Camurus Overview
About Camurus
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.
Founded
2004
HQ
Employees
256
Website
Sectors
Financials (LTM)
EV
$3B
Camurus Financials
Camurus reported last 12-month revenue of $270M and EBITDA of $106M.
In the same LTM period, Camurus generated $232M in gross profit, $106M in EBITDA, and $89M in net income.
Revenue (LTM)
Camurus P&L
In the most recent fiscal year, Camurus reported revenue of $255M and EBITDA of $105M.
Camurus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $270M | XXX | $255M | XXX | XXX | XXX |
| Gross Profit | $232M | XXX | $229M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $106M | XXX | $105M | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 41% | XXX | XXX | XXX |
| EBIT Margin | 39% | XXX | 39% | XXX | XXX | XXX |
| Net Profit | $89M | XXX | $83M | XXX | XXX | XXX |
| Net Margin | 33% | XXX | 32% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Camurus Stock Performance
Camurus has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Camurus' stock price is $62.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 1.8% | XXX | XXX | XXX | $1.38 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCamurus Valuation Multiples
Camurus trades at 12.5x EV/Revenue multiple, and 31.9x EV/EBITDA.
EV / Revenue (LTM)
Camurus Financial Valuation Multiples
As of April 18, 2026, Camurus has market cap of $4B and EV of $3B.
Equity research analysts estimate Camurus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Camurus has a P/E ratio of 42.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 12.5x | XXX | 13.2x | XXX | XXX | XXX |
| EV/EBITDA | 31.9x | XXX | 32.1x | XXX | XXX | XXX |
| EV/EBIT | 32.4x | XXX | 34.3x | XXX | XXX | XXX |
| EV/Gross Profit | 14.5x | XXX | 14.7x | XXX | XXX | XXX |
| P/E | 42.3x | XXX | 45.5x | XXX | XXX | XXX |
| EV/FCF | 46.1x | XXX | 42.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Camurus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Camurus Margins & Growth Rates
Camurus' revenue in the last 12 month grew by 28%.
Camurus' revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.5M for the same period.
Camurus' rule of 40 is 63% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Camurus' rule of X is 100% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Camurus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | 41% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 63% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 100% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 24% | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Camurus Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Camurus | XXX | XXX | XXX | XXX | XXX | XXX |
| Travere Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ACADIA Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ajanta Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Voronoi | XXX | XXX | XXX | XXX | XXX | XXX |
| Tango Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Camurus M&A Activity
Camurus acquired XXX companies to date.
Last acquisition by Camurus was on XXXXXXXX, XXXXX. Camurus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Camurus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCamurus Investment Activity
Camurus invested in XXX companies to date.
Camurus made its latest investment on XXXXXXXX, XXXXX. Camurus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Camurus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Camurus
| When was Camurus founded? | Camurus was founded in 2004. |
| Where is Camurus headquartered? | Camurus is headquartered in Sweden. |
| How many employees does Camurus have? | As of today, Camurus has over 256 employees. |
| Who is the CEO of Camurus? | Camurus' CEO is Fredrik Tiberg. |
| Is Camurus publicly listed? | Yes, Camurus is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Camurus? | Camurus trades under CAMX ticker. |
| When did Camurus go public? | Camurus went public in 2015. |
| Who are competitors of Camurus? | Camurus main competitors are Travere Therapeutics, ACADIA Pharmaceuticals, Ajanta Pharma, Voronoi. |
| What is the current market cap of Camurus? | Camurus' current market cap is $4B. |
| What is the current revenue of Camurus? | Camurus' last 12 months revenue is $270M. |
| What is the current revenue growth of Camurus? | Camurus revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of Camurus? | Current revenue multiple of Camurus is 12.5x. |
| Is Camurus profitable? | Yes, Camurus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Camurus? | Camurus' last 12 months EBITDA is $106M. |
| What is Camurus' EBITDA margin? | Camurus' last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Camurus? | Current EBITDA multiple of Camurus is 31.9x. |
| What is the current FCF of Camurus? | Camurus' last 12 months FCF is $73M. |
| What is Camurus' FCF margin? | Camurus' last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of Camurus? | Current FCF multiple of Camurus is 46.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.